Comparative Pharmacology
Head-to-head clinical analysis: NAGLAZYME versus VPRIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAGLAZYME versus VPRIV.
NAGLAZYME vs VPRIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
VPRIV (velaglucerase alfa) is a recombinant form of human lysosomal glucocerebrosidase that hydrolyzes glucocerebroside to glucose and ceramide, replacing the deficient enzyme in Gaucher disease.
1 mg/kg intravenously once weekly.
60 U/kg intravenously every 2 weeks over 4 hours.
None Documented
None Documented
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
Terminal elimination half-life is approximately 30 minutes (range 15-60 minutes) in Gaucher disease patients, necessitating intravenous infusion over 1-2 hours every other week.
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Primarily metabolized via peptide hydrolysis; elimination is predominantly non-renal. Renal excretion accounts for <5% of the dose as intact drug. Fecal elimination of metabolites is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy